Skip to main content

MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study

Trial Status: Closed to Accrual

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in subjects with metastatic pancreatic cancer.

Inclusion Criteria

  • Age ≥ 18
  • Written and signed informed consent must be obtained
  • ECOG Performance Status 0 or 1
  • Weight ≥ 35 kg
  • Subjects must have histologically or cytologically, confirmed pancreatic adenocarcinoma: Cohort A: Subjects with previously untreated metastatic pancreatic adenocarcinoma (1st line metastatic disease) not previously treated with systemic therapies. Cohort B: Subjects with metastatic pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy (without exposure to 5-FU, capecitabine, oxaliplatin) 2nd line metastatic disease
  • Subjects must have at least 1 measurable lesion according to RECIST v1.1
  • All subjects must consent to providing archival tumor specimens

Exclusion Criteria

  • Receipt of any conventional or investigational anticancer therapy within 21 days or palliative radiotherapy within 14 days prior to the scheduled first dose of study treatment.
  • Prior receipt of any immune-related therapy
  • Concurrent enrollment in another therapeutic clinical study. Enrollment in observational studies will be allowed
  • Subjects with a history of venous thrombosis within the past 3 months
  • Subjects with prior history of myocardial infarction, transient ischemic attack, or stroke in the last 3 months prior to start of treatment
  • Active or prior documented autoimmune or inflammatory disorders within the past 3 years prior to the start of treatment
  • Other invasive malignancy within 2 years.
  • Any history of leptomeningeal disease or cord compression.
  • Current or prior use of immunosuppressive medication within 14 days prior to the first dose

California

San Diego
University of California San Diego
Status: ACTIVE

Colorado

Aurora
University of Colorado Hospital
Status: TEMPORARILY_CLOSED_TO_ACCRUAL

Georgia

Atlanta
Emory Saint Joseph's Hospital
Status: ACTIVE
Emory University Hospital / Winship Cancer Institute
Status: ACTIVE
Emory University Hospital Midtown
Status: APPROVED

Massachusetts

Boston
Beth Israel Deaconess Medical Center
Status: ACTIVE

Michigan

Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL

New York

Buffalo
Roswell Park Cancer Institute
Status: ACTIVE

North Carolina

Durham
Duke University Medical Center
Status: ACTIVE

Ohio

Columbus
Ohio State University Comprehensive Cancer Center
Status: TEMPORARILY_CLOSED_TO_ACCRUAL

Pennsylvania

Philadelphia
Fox Chase Cancer Center
Status: ACTIVE

Texas

Dallas
UT Southwestern / Simmons Cancer Center-Dallas
Status: ACTIVE
Contact: Marcella West Aguilar
Phone: 214-648-1479
Houston
M D Anderson Cancer Center
Status: ACTIVE

Virginia

Charlottesville
University of Virginia Cancer Center
Status: ACTIVE

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: TEMPORARILY_CLOSED_TO_ACCRUAL

Wisconsin

Madison
University of Wisconsin Hospital and Clinics
Status: TEMPORARILY_CLOSED_TO_ACCRUAL

This is a Phase 1b/2, multicenter, open-label, dose-escalation, and dose-expansion study to assess the safety, preliminary antitumor activity, immunogenicity, and PK of oleclumab with or without durvalumab in combination with chemotherapy administered in subjects with metastatic PDAC. Subjects with previously untreated metastatic PDAC (1L metastatic PDAC) with be enrolled in Cohort A. Subjects with metastatic PDAC previously treated with gemcitabine-based chemotherapy (without exposure to 5-FU, capecitabine, or oxaliplatin, 2L metastatic PDAC) will be enrolled in Cohort B. The study consists of 2 parts, dose escalation (part 1) and dose expansion (Part 2).

Trial Phase Phase I/II

Trial Type Treatment

Lead Organization
MedImmune Inc

  • Primary ID D6070C00005
  • Secondary IDs NCI-2018-01724
  • Clinicaltrials.gov ID NCT03611556